Mai-Britt Zocca - Nov 9, 2021 Form 4 Insider Report for IO Biotech, Inc. (IOBT)

Role: Chief Executive Officer, Director
Signature: /s/ Brian Burkavage, Attorney-in-Fact for Mai-Britt Zocca
Stock symbol: IOBT
Transactions as of: Nov 9, 2021
Transactions value $: $0
Form type: 4
Date filed: 11/12/2021, 03:15 PM
Previous filing: Nov 4, 2021
Next filing: Mar 22, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IOBT	Common Stock	Conversion of derivative security		+26.6K			26.6K	Nov 9, 2021	Zocca Consulting ApS	F1, F2
holding	IOBT	Common Stock						354	Nov 9, 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IOBT	Class A Stock	Conversion of derivative security	$0	-26.6K	-100%	$0.00^*	0	Nov 9, 2021	Common Stock	26.6K		Zocca Consulting ApS	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Upon the closing of the Issuer's initial public offering, each share of Class A Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Class A Stock had no expiration date.
F2	The reporting person is the sole owner of Zocca Consulting ApS and, in such capacity, may be deemed to beneficially own the shares held directly by Zocca Consulting ApS. The reporting person disclaims beneficial ownership of the shares held directly by Zocca Consulting ApS except to the extent of his pecuniary interest therein.